Bio-Path (BPTH) Competitors

$0.06 -0.01 (-11.66%)

As of 12:31 PM Eastern

BPTH vs. SXTC, PTIX, SNOA, CANF, and CNSP

Should you be buying Bio-Path stock or one of its competitors? The main competitors of Bio-Path include China SXT Pharmaceuticals (SXTC), Atrinsic (PTIX), Sonoma Pharmaceuticals (SNOA), Can-Fite BioPharma (CANF), and CNS Pharmaceuticals (CNSP). These companies are all part of the "pharmaceutical products" industry.

How does Bio-Path compare to China SXT Pharmaceuticals?

Bio-Path (NASDAQ:BPTH) and China SXT Pharmaceuticals (NASDAQ:SXTC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio-Path
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
China SXT Pharmaceuticals
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: China SXT Pharmaceuticals has higher revenue and earnings than Bio-Path.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bio-Path N/A N/A -$16.08M -$1.06 N/A
China SXT Pharmaceuticals $1.74M 0.99 -$3.30M N/A N/A
: In the previous week, Bio-Path's average media sentiment score of 0.00 equaled China SXT Pharmaceuticals'average media sentiment score.
Company Overall Sentiment
Bio-Path Neutral
China SXT Pharmaceuticals Neutral
: Bio-Path has a beta of -0.29, meaning that its stock price is 129% less volatile than the S&P 500. Comparatively, China SXT Pharmaceuticals has a beta of 1.96, meaning that its stock price is 96% more volatile than the S&P 500.
: 5.7% of Bio-Path shares are held by institutional investors. Comparatively, 5.0% of China SXT Pharmaceuticals shares are held by institutional investors. 0.7% of Bio-Path shares are held by insiders. Comparatively, 4.0% of China SXT Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
: China SXT Pharmaceuticals' return on equity of 0.00% beat Bio-Path's return on equity.
Company Net Margins Return on Equity Return on Assets
Bio-Path N/A -2,842.40% -337.48%
China SXT Pharmaceuticals N/A N/A N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Path	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
China SXT Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Path	N/A	N/A	-$16.08M	-$1.06	N/A
China SXT Pharmaceuticals	$1.74M	0.99	-$3.30M	N/A	N/A

Company	Overall Sentiment
Bio-Path	Neutral
China SXT Pharmaceuticals	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Bio-Path	N/A	-2,842.40%	-337.48%
China SXT Pharmaceuticals	N/A	N/A	N/A

Summary

China SXT Pharmaceuticals beats Bio-Path on 7 of the 8 factors compared between the two stocks.

How does Bio-Path compare to Atrinsic?

Bio-Path (NASDAQ:BPTH) and Atrinsic (NASDAQ:PTIX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

: Atrinsic's return on equity of 0.00% beat Bio-Path's return on equity.
Company Net Margins Return on Equity Return on Assets
Bio-Path N/A -2,842.40% -337.48%
Atrinsic N/A N/A -379.72%
: 5.7% of Bio-Path shares are held by institutional investors. Comparatively, 8.0% of Atrinsic shares are held by institutional investors. 0.7% of Bio-Path shares are held by insiders. Comparatively, 8.0% of Atrinsic shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
: Atrinsic is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bio-Path N/A N/A -$16.08M -$1.06 N/A
Atrinsic N/A N/A -$5.53M -$3.45 N/A
: Bio-Path has a beta of -0.29, meaning that its stock price is 129% less volatile than the S&P 500. Comparatively, Atrinsic has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500.
: In the previous week, Bio-Path's average media sentiment score of 0.00 equaled Atrinsic'saverage media sentiment score.
Company Overall Sentiment
Bio-Path Neutral
Atrinsic Neutral
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio-Path
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Atrinsic
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00

Company	Net Margins	Return on Equity	Return on Assets
Bio-Path	N/A	-2,842.40%	-337.48%
Atrinsic	N/A	N/A	-379.72%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Path	N/A	N/A	-$16.08M	-$1.06	N/A
Atrinsic	N/A	N/A	-$5.53M	-$3.45	N/A

Company	Overall Sentiment
Bio-Path	Neutral
Atrinsic	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Path	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Atrinsic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Atrinsic beats Bio-Path on 6 of the 9 factors compared between the two stocks.

How does Bio-Path compare to Sonoma Pharmaceuticals?

Bio-Path (NASDAQ:BPTH) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

: Sonoma Pharmaceuticals has higher revenue and earnings than Bio-Path. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bio-Path N/A N/A -$16.08M -$1.06 N/A
Sonoma Pharmaceuticals $14.29M 0.15 -$3.46M -$2.04 N/A
: 5.7% of Bio-Path shares are owned by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are owned by institutional investors. 0.7% of Bio-Path shares are owned by insiders. Comparatively, 24.6% of Sonoma Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
: In the previous week, Bio-Path's average media sentiment score of 0.00 equaled Sonoma Pharmaceuticals'average media sentiment score.
Company Overall Sentiment
Bio-Path Neutral
Sonoma Pharmaceuticals Neutral
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio-Path
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Sonoma Pharmaceuticals
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: Bio-Path has a beta of -0.29, indicating that its share price is 129% less volatile than the S&P 500. Comparatively, Sonoma Pharmaceuticals has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500.
: Bio-Path has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -19.04%. Sonoma Pharmaceuticals' return on equity of -42.56% beat Bio-Path's return on equity.
Company Net Margins Return on Equity Return on Assets
Bio-Path N/A -2,842.40% -337.48%
Sonoma Pharmaceuticals -19.04% -42.56% -11.97%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Path	N/A	N/A	-$16.08M	-$1.06	N/A
Sonoma Pharmaceuticals	$14.29M	0.15	-$3.46M	-$2.04	N/A

Company	Overall Sentiment
Bio-Path	Neutral
Sonoma Pharmaceuticals	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Path	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Bio-Path	N/A	-2,842.40%	-337.48%
Sonoma Pharmaceuticals	-19.04%	-42.56%	-11.97%

Summary

Sonoma Pharmaceuticals beats Bio-Path on 7 of the 11 factors compared between the two stocks.

How does Bio-Path compare to Can-Fite BioPharma?

Can-Fite BioPharma (NYSE:CANF) and Bio-Path (NASDAQ:BPTH) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

: Can-Fite BioPharma currently has a consensus target price of $65.00, suggesting a potential upside of 1,757.14%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe Can-Fite BioPharma is more favorable than Bio-Path.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Can-Fite BioPharma
0 Sell rating(s)
2 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.33
Bio-Path
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Can-Fite BioPharma's return on equity of 0.00% beat Bio-Path's return on equity.
Company Net Margins Return on Equity Return on Assets
Can-Fite BioPharma N/A N/A N/A
Bio-Path N/A -2,842.40% -337.48%
: Can-Fite BioPharma has higher revenue and earnings than Bio-Path. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Can-Fite BioPharma $405K 5.66 -$7.63M -$35.80 N/A
Bio-Path N/A N/A -$16.08M -$1.06 N/A
: In the previous week, Can-Fite BioPharma had 2 more articles in the media than Bio-Path. MarketBeat recorded 2 mentions for Can-Fite BioPharma and 0 mentions for Bio-Path. Can-Fite BioPharma's average media sentiment score of 0.34 beat Bio-Path's score of 0.00 indicating that Can-Fite BioPharma is being referred to more favorably in the media.
Company Overall Sentiment
Can-Fite BioPharma Neutral
Bio-Path Neutral
: Can-Fite BioPharma has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, Bio-Path has a beta of -0.29, meaning that its stock price is 129% less volatile than the S&P 500.
: 21.0% of Can-Fite BioPharma shares are held by institutional investors. Comparatively, 5.7% of Bio-Path shares are held by institutional investors. 0.8% of Can-Fite BioPharma shares are held by company insiders. Comparatively, 0.7% of Bio-Path shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Can-Fite BioPharma	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
Bio-Path	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Net Margins	Return on Equity	Return on Assets
Can-Fite BioPharma	N/A	N/A	N/A
Bio-Path	N/A	-2,842.40%	-337.48%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Can-Fite BioPharma	$405K	5.66	-$7.63M	-$35.80	N/A
Bio-Path	N/A	N/A	-$16.08M	-$1.06	N/A

Company	Overall Sentiment
Can-Fite BioPharma	Neutral
Bio-Path	Neutral

Summary

Can-Fite BioPharma beats Bio-Path on 12 of the 14 factors compared between the two stocks.

How does Bio-Path compare to CNS Pharmaceuticals?

Bio-Path (NASDAQ:BPTH) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

: CNS Pharmaceuticals has a consensus target price of $20.00, suggesting a potential upside of 179.72%. Given CNS Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe CNS Pharmaceuticals is more favorable than Bio-Path.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio-Path
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
CNS Pharmaceuticals
1 Sell rating(s)

0 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.33
: CNS Pharmaceuticals' return on equity of -164.56% beat Bio-Path's return on equity.
Company Net Margins Return on Equity Return on Assets
Bio-Path N/A -2,842.40% -337.48%
CNS Pharmaceuticals N/A -164.56% -130.05%
: CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bio-Path N/A N/A -$16.08M -$1.06 N/A
CNS Pharmaceuticals N/A N/A -$15.85M -$41.30 N/A
: In the previous week, CNS Pharmaceuticals had 3 more articles in the media than Bio-Path. MarketBeat recorded 3 mentions for CNS Pharmaceuticals and 0 mentions for Bio-Path. CNS Pharmaceuticals' average media sentiment score of 0.97 beat Bio-Path's score of 0.00 indicating that CNS Pharmaceuticals is being referred to more favorably in the news media.
Company Overall Sentiment
Bio-Path Neutral
CNS Pharmaceuticals Positive
: Bio-Path has a beta of -0.29, meaning that its share price is 129% less volatile than the S&P 500. Comparatively, CNS Pharmaceuticals has a beta of 2.62, meaning that its share price is 162% more volatile than the S&P 500.
: 5.7% of Bio-Path shares are held by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are held by institutional investors. 0.7% of Bio-Path shares are held by insiders. Comparatively, 0.0% of CNS Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Path	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Company	Net Margins	Return on Equity	Return on Assets
Bio-Path	N/A	-2,842.40%	-337.48%
CNS Pharmaceuticals	N/A	-164.56%	-130.05%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Path	N/A	N/A	-$16.08M	-$1.06	N/A
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$41.30	N/A

Company	Overall Sentiment
Bio-Path	Neutral
CNS Pharmaceuticals	Positive

Summary

CNS Pharmaceuticals beats Bio-Path on 10 of the 13 factors compared between the two stocks.

Get Bio-Path News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BPTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BPTH vs. The Competition

Export

Metric	Bio-Path	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$517K	$886.55M	$6.25B	$11.77B
Dividend Yield	N/A	4.84%	2.74%	5.26%
P/E Ratio	-0.05	0.96	24.91	23.23
Price / Sales	N/A	120.65	504.56	75.49
Price / Cash	N/A	20.07	43.30	53.90
Price / Book	0.08	7.60	9.67	6.69
Net Income	-$16.08M	-$4.80M	$3.55B	$332.64M
7 Day Performance	N/A	-0.05%	1.70%	2.01%
1 Month Performance	N/A	5.50%	5.62%	9.19%
1 Year Performance	N/A	30.96%	34.42%	39.59%

Bio-Path Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BPTH Bio-Path	N/A	$0.06 -11.7%	N/A	N/A	$517K	N/A	N/A	10	Upcoming Earnings Gap Up
SXTC China SXT Pharmaceuticals	0.6089 of 5 stars	$2.09 +0.5%	N/A	N/A	$2M	$1.74M	N/A	90	Gap Down
PTIX Atrinsic	N/A	$1.08 +11.2%	N/A	N/A	$1.96M	N/A	N/A	2	Upcoming Earnings
SNOA Sonoma Pharmaceuticals	0.7086 of 5 stars	$1.04 -6.3%	N/A	N/A	$1.92M	$17.72M	N/A	180
CANF Can-Fite BioPharma	1.7089 of 5 stars	$2.91 -0.3%	$65.00 +2,133.7%	N/A	$1.91M	$405K	N/A	8	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BPTH) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bio-Path (BPTH) Competitors

BPTH vs. SXTC, PTIX, SNOA, CANF, and CNSP

How does Bio-Path compare to China SXT Pharmaceuticals?

Summary

How does Bio-Path compare to Atrinsic?

Summary

How does Bio-Path compare to Sonoma Pharmaceuticals?

Summary

How does Bio-Path compare to Can-Fite BioPharma?

Summary

How does Bio-Path compare to CNS Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPTH vs. The Competition

Bio-Path Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bio-Path (BPTH) Competitors

BPTH vs. SXTC, PTIX, SNOA, CANF, and CNSP

How does Bio-Path compare to China SXT Pharmaceuticals?

Summary

How does Bio-Path compare to Atrinsic?

Summary

How does Bio-Path compare to Sonoma Pharmaceuticals?

Summary

How does Bio-Path compare to Can-Fite BioPharma?

Summary

How does Bio-Path compare to CNS Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPTH vs. The Competition

Bio-Path Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools